Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZT4J
|
|||
| Former ID |
DCL000012
|
|||
| Drug Name |
JSM 6427
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 1 | [1] | |
| Company |
Jerini AG
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00536016) A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. U.S. National Institutes of Health. | |||
| REF 2 | An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. | |||
| REF 3 | Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res. 2007 Sep;32(9):801-12. | |||
| REF 4 | Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 2006 Jun;69(6):1820-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.